$1.320
-0.029 (-2.22%)收盘时
价格预测
在 App 中打开以解锁更长周期的预测。
NGEN 相似图表分析预测
Alphio's NGEN stock price prediction model matches the current NervGen Pharma Corp tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.31 (-0.69%). The 1-week path is $1.26 (-4.45%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
该买入 NervGen Pharma Corp 股票吗?
Nervgen Pharma Corp. is not a good buy right now. The current price is $1.35, which is significantly below the 52-week high of $6.30, indicating a steep decline of 78.40% year-to-date. Additionally, the RSI is at a very low 21.92, suggesting oversold conditions, but this may not be a strong enough signal to counteract the negative financial performance, including a net income loss of CAD 29,217,233 in Q2 2026. The main risk is the ongoing equity dilution from the recent public offering, which could further depress the stock price.
NGEN 股价于 Thursday 收于 $1.32,此前下跌 -2.22%
NervGen Pharma Corp (NGEN) last closed at $1.3200001, losing -2.22%. These facts feed the 1-day and 1-week NGEN price prediction above.
预测驱动因素
NervGen Pharma Corp(NGEN)的预测驱动因素综合了相似的图表形态、季节性与移动平均线。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
相似图表形态
近期走势与 NGEN 最接近的股票,按相似度排序。
NGEN 季节性分析
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。